Literature DB >> 30790382

Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer.

Mary Anne Tanay1, Jo Armes2.   

Abstract

OBJECTIVES: This study explored lived experiences of women who developed chemotherapy-induced peripheral neuropathy (CIPN) following treatment for breast and ovarian cancer. It also explored cancer survivors' perceptions of information and advice offered by clinicians about CIPN and for managing CIPN.
METHODS: The study was advertised through cancer charity websites and social media accounts. Purposeful, convenience sampling was carried out using set eligibility criteria. Individuals with diagnosis of breast or ovarian cancer who experienced or are still experiencing CIPN were recruited. Fifteen semi-structured interviews were conducted. Data were analysed using interpretative phenomenological analysis (IPA).
RESULTS: Similar to previous studies, participants used comparisons to describe their symptoms. Four main themes emerged from the analysis: (a) struggle to process CIPN information, (b) information and trust are key in the treatment decision-making process, (c) experience of symptom reporting and (d) challenges of managing symptoms. Findings suggest interventions to improve understanding of CIPN risk are needed in practice.
CONCLUSION: A better and broader understanding of the patient experience of CIPN could pave the way for improved communication, assessment and management of symptoms. Results suggest the need for interventions to guide cancer survivors to recognise and report CIPN symptoms early and address the impact of CIPN symptoms in their lives.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer; chemotherapy; chemotherapy-induced peripheral neuropathy; patient experience; phenomenology; survivorship

Mesh:

Substances:

Year:  2019        PMID: 30790382     DOI: 10.1111/ecc.13011

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  6 in total

Review 1.  Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials.

Authors:  Katie Fitzgerald Jones; Stephen Wechsler; David Zulewski; Lisa Wood
Journal:  J Palliat Med       Date:  2022-02-04       Impact factor: 2.947

2.  Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.

Authors:  Robert Knoerl; Emanuele Mazzola; Fangxin Hong; Elahe Salehi; Nadine McCleary; Jennifer Ligibel; Kaitlen Reyes; Donna L Berry
Journal:  BMC Cancer       Date:  2021-03-06       Impact factor: 4.430

3.  A new self-understanding as chemo sufferer - a phenomenological study of everyday life with chemotherapy induced neuropathy among survivors after colorectal cancer.

Authors:  Marlene Ae Jensen; Carsten D Mørch; Mette N Yilmaz; Casper Feilberg; Birgith Pedersen
Journal:  Int J Qual Stud Health Well-being       Date:  2022-12

4.  Co-designing a cancer care intervention: reflections of participants and a doctoral researcher on roles and contributions.

Authors:  Mary Anne Lagmay Tanay; Jo Armes; Catherine Oakley; Lesley Sage; Deb Tanner; Jose Roca; Liz Bryson; Barbara Greenall; Lauren Urwin; Toni Wyatt; Glenn Robert
Journal:  Res Involv Engagem       Date:  2022-08-02

5.  Cancer Survivors' Perspectives of Virtual Yoga for Chronic Chemotherapy-Induced Peripheral Neuropathy Pain During the COVID-19 Pandemic.

Authors:  Robert Knoerl; Julianna Bockhoff; Erica Fox; Anita Giobbie-Hurder; Donna L Berry; Juliana Berfield; Jeffrey Meyerhardt; Alexi Wright; Jennifer Ligibel
Journal:  Comput Inform Nurs       Date:  2022-09-01       Impact factor: 2.146

6.  Effects of Laparoscopic Hyperthermic Perfusion Therapy Combined with Adjuvant Treatment of Compound Yew Capsule on Ovarian Blood Flow Parameters and Immune Function in Patients with Ovarian Cancer.

Authors:  Mengya Su; Donghui Wang; Ping Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-13       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.